FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
WEBJun 17, 2024 · KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch repair status. Approval marks the third FDA-approved indication for KEYTRUDA in endometrial carcinoma and the 40 th indication for KEYTRUDA in the US
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) …
WEBMay 5, 2021 · KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10) as …
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
WEBNov 16, 2023 · Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone. Approval marks seventh gastrointestinal cancer indication for KEYTRUDA-based regimens and 38th indication for KEYTRUDA in the US.
FDA approves pembrolizumab with chemotherapy for …
WEB4 days ago · On September 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or...
FDA approves pembrolizumab with chemotherapy for …
WEBOn June 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with...
FDA approves pembrolizumab with chemotherapy for HER2 …
WEBOn November 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) …
WEB5 days ago · MRK. At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab.
Padcev and Keytruda Double Bladder Cancer Survival - NCI
WEBNov 30, 2023 · One treatment—the combination of enfortumab vedotin (Padcev) and the immunotherapy drug pembrolizumab (Keytruda)—proved to be particularly powerful. The findings mark a pivotal moment following years of little progress, according to several leading bladder cancer experts.
FDA Approves Pembrolizumab with Chemotherapy for …
WEB2 days ago · On 17 September 2024, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Pembrolizumab to Prevent Early-Stage Melanoma Recurrence
WEBOct 13, 2021 · Patients who received the immunotherapy pembrolizumab (Keytruda) after surgery to remove high-risk stage II melanomas were less likely to have the cancer come back than those who received no post-surgical treatment, new study results show.
Skip to content